NCT02503423 2026-03-20
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Taiho Oncology, Inc.
Phase 1/2 Active not recruiting
Clinical Trials
9 trialsNCT04362007 2026-02-25
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
Otsuka Pharmaceutical Co., Ltd.
Phase 1/2 Terminated
NCT05403450 2026-02-23
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Taiho Oncology, Inc.
Phase 1 Active not recruiting
NCT05082259 2026-02-10
ASTEROID
Institute of Cancer Research, United Kingdom
Phase 1 Recruiting
NCT05245682 2026-01-08
Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
Emory University
Phase EARLY_PHASE1 Active not recruiting
NCT06590558 2025-07-03
Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT06393751 2025-06-03
Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT04155580 2024-08-02
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Astex Pharmaceuticals, Inc.
Phase 1 Terminated
NCT05912075 2024-02-08
PRAAR1
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Recruiting